A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

NCT ID: NCT02426034

Last Updated: 2022-07-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 2004 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-05-15
• Study Completion Date: 2020-09-03

Brief Summary

The large-scale phase IV study aims to verify the safety and efficacy of apatinib in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma after failure of two lines of chemotherapy. Apatinib initiated at a recommended dose of 850mg. However, the starting dose was decided by investigator's choice based on patients' condition. Dose interruption and dose reduction were allowed according to the product label. Treatment continued until disease progression, intolerable toxicity, withdrawal of informed consent, or at investigators' discretion. The primary endpoint was safety, which was assessed by recording the incidence and severity of adverse events.

Conditions

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment group

Apatinib Tablets

Group Type: EXPERIMENTAL

ApatinibTablets

Intervention Type: DRUG

Apatinib Tablets, recommended dose of 850mg

Interventions

ApatinibTablets

Apatinib Tablets, recommended dose of 850mg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age: 18 to75 years old;

2. Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction);

3. Failure of prior therapy (during or after treatment) in patients who have received at least two prior chemotherapy regimens;

4. ECOG PS of 0-2;

5. Major organ function has to meet the following criteria:

For results of blood routine test (without blood transfusion within 14 days):

HB ≥ 90g / L ANC ≥ 1.5 × 109 / L PLT ≥ 80 × 109 / L

Biochemical tests results:

Bilirubin <1.25 times the upper limit of normal (ULN) ALT and AST <2.5 × ULN; liver metastases, if any, the ALT and AST<5 × ULN Serum Cr ≤ 1 × ULN endogenous creatinine clearance>50ml/min (Cockcroft-Gault formula)

6. An expected survival of ≥ 3 months;

7. Patient received apatinib treatment regimen at investigators' discretion;

8. Patient has to voluntarily join the study and sign the Informed Consent Form for the study;

9. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.

Exclusion Criteria

1. Subjects with uncontrolled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Grade ≥ 2 coronary heart disease; Grade ≥ 2 arrhythmia (including QT interval prolongation, for man > 450 ms, for woman > 470 ms), as well as Grade ≥ 2 cardiac dysfunction;

2. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);

3. Subjects with high gastrointestinal bleeding risk, including the following conditions: presence of active ulceration combined with a positive fecal occult blood test (++);history of hematemesis and melena within three months before enrollment; unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy finding;

4. Abnormal coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleeding;

5. Presence of central nervous system metastases;

6. Pregnant or lactating women;

7. Other conditions regimented at investigators' discretion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jin Li, MD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Nanjin Military 81 Hosiptal

Nanjing, Jiangsu, China

Fudan University cancer hospital

Shanghai, Shanghai Municipality, China

Countries

China

References

Li J, Qin S, Wen L, Wang J, Deng W, Guo W, Jia T, Jiang D, Zhang G, He Y, Ba Y, Zhong H, Wang L, Lin X, Yang J, Zhao J, Bai Y, Wu X, Gao F, Sun G, Wu Y, Ye F, Wang Q, Xie Z, Yi T, Huang Y, Yu G, Lu L, Yuan Y, Li W, Liu L, Sun Y, Sun Y, Yin L, Hou Z. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study. BMC Med. 2023 May 5;21(1):173. doi: 10.1186/s12916-023-02841-7.

Reference Type: DERIVED

PMID: 37147645 (View on PubMed)

Other Identifiers

Ahead-G201

Identifier Type: -

Identifier Source: org_study_id